Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 202

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 202
---
 of the income
statement, in addition to disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15,
2026, with early adoption permitted. The amendment may be applied either prospectively to financial statements issued for reporting periods
after the effective date or retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating
ASU 2024-03 to determine the impact it may have on its consolidated financial statements and related disclosures.

<div align='center'>F-16</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

Predecessor:

The Financial
Statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).

| a. | Use of estimates in preparation of Financial Statements: |

The preparation
of Financial Statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect
the amounts reported in the consolidated Financial Statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions.
The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available
at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the dates of the consolidated Financial Statements, and the reported amounts of expenses during
the reporting periods. Actual results could differ from those estimates.

As applicable
to the Financial Statements, the most significant estimates and assumptions relate to the going concern assumptions and determining the
fair value of options to granted to the Company’s employee is considered substantial.

| b. | Functional currency: |

The functional
currency of the Company and the presentation currency of the financial statements is the U.S. dollar.

Transactions
and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than
the dollar are re-measured into dollars in accordance with ASC No. 830, “Foreign Currency Matters”. All transaction
gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive
loss as financial income or expenses, as appropriate.

| c. | Cash and cash equivalents: |

Cash equivalents
are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less